Exelixis (EXEL) Announced Updated Phase 1b Results for Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at ASCO 2018
Tweet Send to a Friend
Exelixis, Inc. (NASDAQ: EXEL) today announced the presentation of updated results from the Genentech-sponsored phase 1b clinical trial of cobimetinib ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
